GlassScriptPhysician profile
Alexander Marotta
NPI 1720048077
$12,112.01
in general payments reported to CMS, 2019-2025
35 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $323 · 2021: $769 · 2022: $1,264 · 2023: $3,174 · 2024: $2,562 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,937 · Consulting Fee: $863 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,937.29 |
| Consulting Fee | $863.19 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,697.97 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,761.39 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,602.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $680.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $526.97 | 2019-2025 | Dupixent |
| Optinose US, INC. | $518.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $510.02 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $407.04 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Kaleo, INC. | $388.41 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $383.86 | 2021-2025 | Xembify |
| Amgen INC. | $337.55 | 2022-2025 | Tezspire |
| Abbvie INC. | $279.72 | 2022-2024 | |
| Genentech USA, INC. | $204.54 | 2019-2025 | Xolair |
| Lilly USA, LLC | $200.86 | 2024-2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $170.44 | 2022-2025 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $160.45 | 2024-2025 | Adbry |
| Pfizer INC. | $154.79 | 2020-2025 | |
| Cycle Pharmaceuticals INC | $147.58 | 2024-2025 | Sajazir |
| Blueprint Medicines Corporation | $131.00 | 2023-2025 | Ayvakit |
| Galderma Laboratories, L.P. | $94.97 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $88.37 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $85.64 | 2025 | Neffy |
| Octapharma USA, INC. | $72.66 | 2019-2025 | Cutaquig, Panzyga |
| Aimmune Therapeutics, INC. | $70.05 | 2021-2022 | |
| Pharming Healthcare, INC. | $65.23 | 2022-2024 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.06 | 2019-2022 | |
| Alk-Abello, INC | $54.41 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Ionis Pharmaceuticals, INC. | $53.72 | 2025 | Dawnzera |
| Organon LLC | $52.43 | 2025 | |
| Circassia INC. | $43.30 | 2019-2020 | |
| Adma Biomanufacturing LLC | $38.19 | 2025 | |
| Hikma Pharmaceuticals USA | $27.67 | 2024 | Ryaltris |
| Invivyd INC | $19.00 | 2025 | Pemgarda |
| Gc Biopharma USA, INC. | $14.75 | 2025 | Alyglo |
| Mylan Specialty L.P. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Marotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.